Zhihong (Hana) Yun, BSc - De Perrot Research Lab

Marc de Perrot

Reply to the Letter to the Editor: Rethinking the clinical utility of machine learning for CTEPH severity November 28, 2025
No abstract
Endothelin-1 overexpression in pulmonary endarterectomy specimens of CTEPH patients is associated with pulmonary hypertension development September 27, 2025
CONCLUSIONS: ET-1 release from thromboembolic material of CTEPH patients could be an important mechanism leading to PH. Hence, ET-1 receptor antagonists should continue to be investigated as a potential therapeutic agent in CTEPH patients.
The Tempest Surrounding Lung Transplant for Lung Cancer, With Lung Cancer, or With Isolated Lung Metastases September 12, 2025
Lung transplantation for cancer is controversial. The hesitancy has largely been driven by historical outcomes. However, early-stage lung cancer does not significantly affect the outcome of lung transplant for other end-stage lung diseases. We have also made more donor lungs available and hence can consider transplanting patients where the only curative option is to resect […]
One thousand cases of ex vivo lung perfusion for lung transplantation: A single-center experience September 5, 2025
CONCLUSIONS: Ex vivo lung perfusion has emerged as a safe, effective, and scalable platform for donor lung evaluation. Its integration into clinical practice has supported broader donor organ use and excellent patient outcomes, while laying the foundation for continued innovation in lung transplantation.
Utility of machine learning for predicting severe chronic thromboembolic pulmonary hypertension based on CT metrics in a surgical cohort August 23, 2025
CONCLUSIONS: While measures of PE burden had little bearing on PH severity independently, the RV/LV ratio, extent of disease in various segments, total webs observed, and patient demographics improved performance of machine learning models in identifying severe PH.
Management of chronic thromboembolic pulmonary hypertension July 13, 2025
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe and progressive disease. Three treatment modalities are available: pulmonary endarterectomy, balloon pulmonary angioplasty, and pulmonary hypertension (PH) medical therapy. Both mechanical therapies may also be considered in patients with chronic thromboembolic pulmonary disease without PH. Patients should be referred to expert centers, as full surgical evaluation is […]
Ex vivo lung perfusion of pediatric lungs July 11, 2025
No abstract
Intraoperative Surgical Margin Assessment of Sublobar Lung Resection Specimens Using Computed Tomography June 25, 2025
CONCLUSIONS: SM measurement by CT is feasible and has the potential to aid in the evaluation of SM intraoperatively. However, surgeons must anticipate the potentially greater discordance when using this technique for subsolid tumors.
Health Utility and Symptom Scores in Patients With Advanced Malignant Pleural Mesothelioma Treated in a Real-World Setting June 9, 2025
CONCLUSIONS: Baseline quality of life burden is high in patients with aMPM and is well captured by both EQ-5D and ESAS Individual ESAS and pro-CTCAE domains reported low/moderate correlations with HUS, reflecting the inability of one symptom to predict the entire disease state, thus paving the way for future mapping studies. The baseline physical symptom […]
Neoadjuvant Osimertinib for Resectable <em>EGFR</em>-Mutated Non-Small Cell Lung Cancer June 2, 2025
CONCLUSION: Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, EGFR-mutated, stage II-IIIB NSCLC.
A Response to the Letter to the Editor: MARS2 Perspective May 10, 2025
No abstract
Long-segment tracheal resection and reconstruction with a costal cartilage strut reinforced forearm free flap April 17, 2025
No abstract
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative April 4, 2025
The Marathon of Hope Cancer Centres Network (MOHCCN), led by the Terry Fox Research Institute and the Terry Fox Foundation, unites researchers, clinicians, patients, funders, and other partners across Canada to accelerate precision oncology, promote collaboration and data sharing, and ultimately improve patient outcomes. This overview outlines the Network's goals, history, and challenges and opportunities. […]
Computed tomography identifies sex-specific differences in surgical chronic thromboembolic pulmonary hypertension March 27, 2025
CONCLUSIONS: Sex-specific differences in chronic thromboembolic pulmonary hypertension are demonstrated on computed tomography pulmonary angiography in overall distribution and lesion type at the segmental and subsegmental level with women having fewer and more distal lesions despite similar hemodynamics.
Mesothelioma cell heterogeneity identified by single cell RNA sequencing March 14, 2025
Mesothelioma cell heterogeneity encompasses diverse morphological and molecular characteristics observed within tumors, significantly impacting disease progression, treatment outcomes, and the development of targeted therapies. This heterogeneity has long posed challenges for accurate diagnosis and effective treatment, but understanding its complexities offers the potential for novel diagnostic modalities and therapeutic interventions. This study employed single-cell RNA […]

Partners: Latner Labs

University of Toronto

University Health Network